Ebola virus is one of the two members of a family of RNA viruses called the Filoviridae and of the order Mononegavirales. Ebola HF is an important emerging infection in central Africa and has received much attention in recent years owing to the documented high case-fatality rates (50% to 90%) associated with past outbreaks. Ebola virus was first identified in 1976 when two outbreaks of Ebola hemorrhagic fever (Ebola HF) occurred in northern Zaire (now the Democratic Republic of Congo) and southern Sudan. Out of five identified subtypes of Ebola virus, four of the five have caused disease in humans: Ebola-Zaire, Ebola-Sudan, Ebola-Ivory Coast and Ebola- Bundibugyo. The fifth, Ebola-Reston, has caused disease in nonhuman primates, but not in humans. The most highly virulent subtype of Ebola is Ebola Zaire whose mortality rate is 88%. About 1850 cases with over 1200 deaths have been documented since the Ebola virus was discovered and average fatality rate is 65%. Due to its highly pathogenic nature, scientific research conducted on Ebola must be conducted in a Biosafety Level 4 Lab (BSL-4).
Immuno-Informatic Speculation and Computational Modeling of Novel MHC-II Human Leukocyte Antigenic Alleles to Elicit Vaccine for Ebola Virus: Arpit Saraswat, Shraddha, Amisha Jain, Aakanksha Pathak Sitansu Kumar Verma and Ajay Kumar
Last date updated on November, 2020